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Primary osteosarcoma usually occurs between the ages of 5 and 25 with an approximate annual
incidence of 2.5 per million children (Birch et al. 1980). It is usually highly malignant, metastasising
early, only 25% of patients surviving at 3 years when treated by amputation alone. In the majority of
patients, treatment with amputation alone is usually quickly followed by death from pulmonary
metastases. The last decade has seen a major change in treatment and a considerable improvement in
results. This has come about as a result of several developments: the use of intensive chemotherapy, the
concentration of oncological and orthopaedic expertise and the development of limb-sparing surgery.
Carefully designed clinical trials are now helping to resolve some of the controversies of the past and are
indicating where future progress must be made; indeed these trials, which of necessity are national
studies, have themselves served to improve standards of care.
Following the introduction of intensive adjuvant chemotherapy, there was, for some years, a question
of whether the apparent dramatic improvement in some studies (Rosen et al., 1982) was due, to a large
extent, to an alteration in 'natural history' and case selection (Taylor et al., 1978; Lange & Levine,
1982). This issue has now been settled. Two trials have been carried out where a control group, treated
with chemotherapy at relapse, was compared with chemotherapy given as adjuvant (Link et al., 1986;
Eilber et al., 1987). Although of slightly different design, these studies have shown a clear benefit in
relapse-free survival in favour of the adjuvant chemotherapy group. The long-term survival with
intensive adjuvant chemotherapy is best shown by the data from West Germany, where in the COSS80
study 65% of patients are relapse-free at 5 years (Winkler et al., 1984, 1988). These data are from a
national study, and although there are stringent entry criteria for the trial, the results are more likely to
represent the general prognosis than single institution studies. These trials have used chemotherapy
based on the T7 and T1O protocol introduced by Rosen et al. (1979, 1982). This scheme is complex and
was evolved by the Sloan-Kettering group in a series of non-randomised studies in the 1970s (Rosen,
1978, 1979). It contains all of the drugs then known to be active in osteosarcoma: high dose
methotrexate (HDMTX), doxorubicin, cisplatin and cyclophosphamide, as well as some which were
probably of little value (bleomycin and actinomycin). The programme is long (44 weeks), toxic, and
relies heavily on HDMTX, especially in the initial stages. The value of HDMTX has been recently
reviewed (Green et al., 1988). It is associated with responses in about 25% of patients with metastatic
disease, but has not been demonstrated to add to the activity of multidrug regimens containing
doxorubicin and platinum. Its expense constitutes a formidable problem. A recent large randomised
trial, conducted by several European groups in collaboration, including the UK Medical Research
Council (The European Osteosarcoma Intergroup: EOI) has shown that results apparently comparable
to those obtained in COSS80 can be obtained with a much shorter regimen using doxorubicin and
cisplatin alone (Bramwell et al., 1988). Since it is clearly of importance to know whether chemotherapy
can be shortened, the collaborative group is now embarked on a randomised comparison of the two
drug regimen and the T1O protocol. If equal, this will allow the development of shorter, more intensive,
treatments, perhaps incorporating new agents with activity, such as ifosfamide (Brade et al., 1985).
Clinically and microscopically osteosarcoma frequently responds to chemotherapy given before
surgery. Pain diminishes rapidly and the tumour shrinks- often considerably. Easily assessable clinical
responses do not always occur, and, in these patients, there is a real danger that surgical removal is
being delayed in a tumour which is not controlled and which may metastasise. There are, as yet, no
reliable methods of detecting early response or progression. Response of bone marrow disease can be
visualised on MRI scanning in leukaemia and other tumours (Cohen et al., 1984) but the role of MRI in
defining osteosarcoma response is not yet clear. Pathological responses are often dramatic and Rosen et
al. (1979) briefly described a scoring system which was said to correlate with risk of relapse. The EOI
pathology group have now introduced a semi-quantitative, reproducible method for scoring response
and this will allow multivariate analysis to determine if histological response is a factor of prognostic
significance independent of tumour size or histological subtype. It is by no means clear that it is correct
to change treatment postoperatively in patients with a poor histological response, to a different regimen
from that given preoperatively (Rosen et al., 1982). It is probably unwise to reserve effective agents such
as cisplatin and doxorubicin for those patients showing a poor histological response. A better strategy
may be to use the most effective agents in all patients (Winkler et al., 1988).
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Since the long-term survival in unselected cases of operable osteosarcoma is now of the order of 60%
it has become difficult to undertake trials with enough power to detect survival improvements smaller
than 10-15%. Trials with more than 400-500 patients are impractical in this rare disease. The United
Kingdom, through the MRC and UK Childrens' Cancer Study Group, is able to recruit 70 patients a
year into treatment trials and, even with collaboration from other European countries, it seems unlikely
that this figure will rise above 100. Since it is probable that it will be more difficult to cure patients who
are not cured by current treatment, it will take a considerable organisational effort to be able to mount
studies of the size necessary to detect further improvements. Future directions will include the
development of shorter but more intensive regimens and the definition of the prognostic factors which
define patients at high risk of failure of chemotherapy response in whom early surgery is advisable.
In the past 8 years there has been a strong move towards limb-sparing surgery where possible. In the
UK the endoprostheses have been custom-made at the Royal National Orthopaedic Hospital at
Stanmore. Preoperative chemotherapy allows time to make the prosthesis, and in responding patients
makes surgery easier by reducing tumour mass. As specialist surgeons have become more familiar with
the approach the indications for conservative surgery have widened and this may mean that more local
recurrences will occur. Limb-sparing surgery is especially valuable in children who are near the end of
their bone growth in whom a gross disparity in leg length is unlikely. The final length of an arm may be
less of a problem compared with the social consequences of amputation of an arm. Endoprosthetic
replacement is a major step forward but extremely close collaboration between experienced surgeons and
oncologists is essential for best results.
Not all patients developing pulmonary metastases will die. In very selected series, when metastases are
completely resected, about 30% of patients will be cured (Goorin et al., 1984). The difficulty lies in
selecting cases for thoracotomy. Patients with late relapse, off treatment, with few metastases will have a
reasonable chance of survival. Relapse while on chemotherapy, multiple bilateral metastases and rapidly
growing metastases all indicate a poor outlook. The criteria for thoracotomy, the value of second-line
chemotherapy and post-thoracotomy lung irradiation have yet to be defined.
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